Doxepin low dose - Somaxon Pharmaceuticals

Drug Profile

Doxepin low dose - Somaxon Pharmaceuticals

Alternative Names: Doxepin low dose; Silenor; SO-101

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Somaxon Pharmaceuticals
  • Developer Endo International; Somaxon Pharmaceuticals
  • Class Antipruritics; Dibenzoxepins; Oxepins; Sleep disorder therapies; Small molecules; Tricyclic antidepressants
  • Mechanism of Action Histamine H1 receptor antagonists; Neurotransmitter uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Insomnia

Most Recent Events

  • 28 Mar 2017 Pernix Therapeutics has patents and pending patent applications for doxepin low-dose in USA
  • 15 Mar 2016 Biomarkers information updated
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top